Docoh
Loading...

112 results

Filter options loading...
Top filers
Top filing types
Recent filing years
8-K
EX-1.1
PCSA Processa Pharmaceuticals Inc
20 Aug 21
Entry into a Material Definitive Agreement
4:30pm
, the revocation, termination, or other impairment of the rights of the Company or any of its subsidiaries under such Permit. (q) Tax Law Compliance. All … United States federal income tax returns of the Company and its subsidiaries required by law to be filed have been filed or extensions thereof have been
10-Q
2021 Q2
PCSA Processa Pharmaceuticals Inc
12 Aug 21
Quarterly report
4:01pm
30, 2021 December 31, 2020 ASSETS Current Assets Cash and cash equivalents Due from related party Due from tax agencies Prepaid expenses and other … lease liability Non-current due to licensor Net deferred tax liability Total Liabilities Commitments and Contingencies Stockholders’ Equity Common
8-K
EX-10.1
PCSA Processa Pharmaceuticals Inc
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
; Payments Books and Reconrds; Audit Rights Tax Matters Payment Method and Currency Conversion Blocked Payments Late Payments ARTICLE VII INTELLECTUAL … shall be fully creditable against future payments. 6.9 Tax Matters. Except as expressly provided below, no payments to be made to Ocuphire
10-Q
2021 Q1
PCSA Processa Pharmaceuticals Inc
13 May 21
Quarterly report
4:30pm
) March 31, 2021 December 31, 2020 ASSETS Current Assets Cash and cash equivalents Due from related party Due from tax agencies Prepaid expenses and other … lease liability Non-current due to licensor Net deferred tax liability Total Liabilities Commitments and Contingencies Stockholders’ Equity Common
DEF 14A
PCSA Processa Pharmaceuticals Inc
22 Apr 21
Definitive proxy
2:00pm
for our employees, including our Named Executive Officers. The plan is intended to qualify as a tax-qualified 401(k) plan so that contributions to the 401(k … . No Liberal Share Reuse. Shares subject to an award will not be available for reuse if such shares are delivered or withheld to satisfy any tax withholding
10-K/A
2020 FY
PCSA Processa Pharmaceuticals Inc
7 Apr 21
Annual report (amended)
4:23pm
officers. The plan is intended to qualify as a tax-qualified 401(k) plan so that contributions to the 401(k) plan, and income earned … , or local tax withholding obligations may or may not be made available for re-issuance under the Omnibus Plan. Transferability. Awards
10-K
2020 FY
EX-10.15
PCSA Processa Pharmaceuticals Inc
24 Mar 21
Annual report
8:00pm
12.14 as follows: 12.14 Tax Withholding. In the event that Processa or any Affiliate is required under applicable Law to deduct and withhold any Taxes … , as defined below) or indemnify Processa or any Affiliate for such Tax amount. Should any payment required to be made to Aposense in accordance
10-K
2020 FY
PCSA Processa Pharmaceuticals Inc
24 Mar 21
Annual report
8:00pm
process. Orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax … ) Interest expense Interest income Total other income (expense) Net Operating Loss Before Income Tax Benefit Income Tax Benefit Net Loss Revenues. We had
8-K
EX-10.1
PCSA Processa Pharmaceuticals Inc
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from the Closing Date. (cc) Tax Status. Except for matters … each (i) has made or filed all United States federal, state and local income and all foreign income and franchise tax returns, reports and declarations
8-K
EX-10.2
PCSA Processa Pharmaceuticals Inc
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
generally to do business in any jurisdiction where it is not then so qualified, subject the Company to any material tax in any such jurisdiction where
8-K
EX-10.3
PCSA Processa Pharmaceuticals Inc
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
. Charges, Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense … transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees
10-Q
2020 Q3
PCSA Processa Pharmaceuticals Inc
12 Nov 20
Quarterly report
4:01pm
-current Liabilities Note payable – Paycheck Protection Program Non-current operating lease liability Net deferred tax liability Total Liabilities … General and administrative expenses Total operating expenses Operating Loss Other Income (Expense) (Note 5) Net Operating Loss Before Income Tax Benefit
8-K
EX-1.1
PCSA Processa Pharmaceuticals Inc
6 Oct 20
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:05pm
all federal, state, local and foreign income and franchise tax returns required to be filed and are not in default in the payment of any taxes which … liability for any tax to be imposed upon the properties or assets of the Company or its subsidiary for which there is not an adequate reserve reflected
424B4
PCSA Processa Pharmaceuticals Inc
5 Oct 20
Prospectus supplement with pricing info
4:16pm
Tax Consequences to Non-U.S. Holders of Our Common Stock Underwriting Legal Matters Experts Where You Can Find More Information Index to Consolidated … franchise tax. Update on COVID-19 Impact The COVID-19 pandemic has been and will likely continue to be extensive in many aspects of society, which
S-1/A
PCSA Processa Pharmaceuticals Inc
30 Sep 20
IPO registration (amended)
4:06pm
Persons Principal Stockholders Description of Our Securities Shares Eligible for Future Sale Material U.S. Federal Income Tax Consequences to Non-U.S … outstanding common stock and our anticipated future needs, and the reduction will reduce our future Delaware franchise tax. Update on COVID-19 Impact
S-1/A
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
Description of Our Securities Shares Eligible for Future Sale Material U.S. Federal Income Tax Consequences to Non-U.S. Holders of Our Common Stock … tax. Update on COVID-19 Impact The COVID-19 pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted
S-1/A
EX-2.1
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
Material Contracts and Obligations Private Placements Brokers or Finders; Other Offers Tax Return and Payments Environmental and Safety Laws Compliance … Environmental and Safety Laws Compliance with Laws; Permits Specific Tax Representations ARTICLE VI COVENANTS Affirmative Covenants of HUWX
S-1/A
EX-4.3
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
. v. Charges, Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other … it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all
S-1/A
EX-1.1
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
and foreign income and franchise tax returns required to be filed and are not in default in the payment of any taxes which were payable pursuant to said … dispute with any taxing authority relating to any of such returns, and the Company has no knowledge of any proposed liability for any tax to be imposed upon
S-1/A
EX-10.5
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
; (iii) excluding the effects of changes in laws or regulations affecting reported results, or changes in tax or accounting principles, regulations or law … ; or (C) Shares tendered or withheld to satisfy federal, state or local tax withholding obligations. 7. Options. Subject to the terms of this Plan